Judy Hsu

Judy’s experience includes advising:

• Five V Capital in relation to the establishment of Five V Fund V ($770 million), Five V Fund IV ($550 million), Five V Fund III ($250 million), Five V Fund II ($100 million), Five V ESVC Fund II, Five V ESVC Fund I, the open-ended Horizons Fund ($100 million) and several separate account mandates with regulated superannuation funds.

• Pemba Capital Partners on the establishment of Pemba Fund III (hard cap reached), Pemba Fund II ($380 million+) and a $650 million management led secondaries fund.

• Quadrant Private Equity with respect to its 7th buyout fund of $1.24 billion and 2nd growth fund of $530 million. 

• Taronga Ventures on the simultaneous restructuring and capital raising for its Real Tech Ventures fund (negotiating across investors including APG, Ivanhoe Cambridge and Qantas Super).

• OIF Ventures on the establishment of its Fund II ($100 million+) and Fund III ($140 million) and Opportunity Fund ($100 million).

• Nash Capital on the establishment of its inaugural PE Fund ($100 million).

• Square Peg Capital with respect to its 2020 Fund ($600 million), 2018 Fund ($350 million) and 2015 Fund ($200 million), and the sale of its major shareholding in Vend Limited (deal value of USD350 million).

• Blackbird Ventures with respect to its $100 million partial secondary sale of portfolio companies to Stepstone and HESTA, and the establishment of its 2020 Core Fund and Follow-on Fund.

• AirTree Ventures on the establishment of its 2019 Fund ($275 million) and 2016 Fund ($250 million).

• Four of the five shortlisted candidates for the Commonwealth’s $500 million Biomedical Translation Fund program, including acting for the three that were successfully licensed: Brandon Capital, OneVentures and BioScience Managers.

• SecondQuarter Ventures on the establishment of its Fund II.